S&P 500   4,170.88 (-0.82%)
DOW   32,800.47 (-0.73%)
QQQ   346.68 (-0.94%)
AAPL   178.45 (+0.65%)
MSFT   329.07 (-0.65%)
META   262.28 (-0.09%)
GOOGL   122.89 (-0.63%)
AMZN   119.25 (-1.98%)
TSLA   195.65 (-2.74%)
NVDA   386.05 (-3.75%)
NIO   7.19 (-2.97%)
BABA   77.79 (-1.12%)
AMD   119.57 (-4.55%)
T   15.78 (+0.90%)
F   12.04 (-4.37%)
MU   68.09 (-5.02%)
CGC   0.80 (-5.63%)
GE   99.94 (-2.40%)
DIS   87.16 (-0.75%)
AMC   4.45 (-3.89%)
PFE   37.73 (+1.95%)
PYPL   61.25 (-1.29%)
NFLX   393.39 (+0.10%)
S&P 500   4,170.88 (-0.82%)
DOW   32,800.47 (-0.73%)
QQQ   346.68 (-0.94%)
AAPL   178.45 (+0.65%)
MSFT   329.07 (-0.65%)
META   262.28 (-0.09%)
GOOGL   122.89 (-0.63%)
AMZN   119.25 (-1.98%)
TSLA   195.65 (-2.74%)
NVDA   386.05 (-3.75%)
NIO   7.19 (-2.97%)
BABA   77.79 (-1.12%)
AMD   119.57 (-4.55%)
T   15.78 (+0.90%)
F   12.04 (-4.37%)
MU   68.09 (-5.02%)
CGC   0.80 (-5.63%)
GE   99.94 (-2.40%)
DIS   87.16 (-0.75%)
AMC   4.45 (-3.89%)
PFE   37.73 (+1.95%)
PYPL   61.25 (-1.29%)
NFLX   393.39 (+0.10%)
S&P 500   4,170.88 (-0.82%)
DOW   32,800.47 (-0.73%)
QQQ   346.68 (-0.94%)
AAPL   178.45 (+0.65%)
MSFT   329.07 (-0.65%)
META   262.28 (-0.09%)
GOOGL   122.89 (-0.63%)
AMZN   119.25 (-1.98%)
TSLA   195.65 (-2.74%)
NVDA   386.05 (-3.75%)
NIO   7.19 (-2.97%)
BABA   77.79 (-1.12%)
AMD   119.57 (-4.55%)
T   15.78 (+0.90%)
F   12.04 (-4.37%)
MU   68.09 (-5.02%)
CGC   0.80 (-5.63%)
GE   99.94 (-2.40%)
DIS   87.16 (-0.75%)
AMC   4.45 (-3.89%)
PFE   37.73 (+1.95%)
PYPL   61.25 (-1.29%)
NFLX   393.39 (+0.10%)
S&P 500   4,170.88 (-0.82%)
DOW   32,800.47 (-0.73%)
QQQ   346.68 (-0.94%)
AAPL   178.45 (+0.65%)
MSFT   329.07 (-0.65%)
META   262.28 (-0.09%)
GOOGL   122.89 (-0.63%)
AMZN   119.25 (-1.98%)
TSLA   195.65 (-2.74%)
NVDA   386.05 (-3.75%)
NIO   7.19 (-2.97%)
BABA   77.79 (-1.12%)
AMD   119.57 (-4.55%)
T   15.78 (+0.90%)
F   12.04 (-4.37%)
MU   68.09 (-5.02%)
CGC   0.80 (-5.63%)
GE   99.94 (-2.40%)
DIS   87.16 (-0.75%)
AMC   4.45 (-3.89%)
PFE   37.73 (+1.95%)
PYPL   61.25 (-1.29%)
NFLX   393.39 (+0.10%)
NASDAQ:NURO

NeuroMetrix (NURO) Stock Forecast, Price & News

$0.97
-0.08 (-7.61%)
(As of 11:32 AM ET)
Compare
Today's Range
$0.96
$1.21
50-Day Range
$0.94
$1.51
52-Week Range
$0.93
$4.73
Volume
1.41 million shs
Average Volume
56,209 shs
Market Capitalization
$7.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NURO stock logo

About NeuroMetrix (NASDAQ:NURO) Stock

NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. Its products include DPNCheck, Quell, and ADVANCE system. It also focuses on the sale of medical equipment and consumables. The company was founded by Shai N. Gozani in June 1996 and is headquartered in Woburn, MA.

Receive NURO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroMetrix and its competitors with MarketBeat's FREE daily newsletter.

NURO Stock News Headlines

146 Pounds of Graphite Needed for Each EV
Graphite - not lithium - is the largest component of lithium-ion batteries used in electric vehicles. That's why 97 more graphite mines will be needed by 2035 just to keep up with battery demand for the $7 trillion EV market.
NeuroMetrix Reports Q1 2023 Financial Results
146 Pounds of Graphite Needed for Each EV
Graphite - not lithium - is the largest component of lithium-ion batteries used in electric vehicles. That's why 97 more graphite mines will be needed by 2035 just to keep up with battery demand for the $7 trillion EV market.
Why NeuroMetrix (NURO) Stock Is Soaring Today
NeuroMetrix Reports Q3 2022 Financial Results
See More Headlines
Receive NURO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroMetrix and its competitors with MarketBeat's FREE daily newsletter.

NURO Company Calendar

Last Earnings
10/17/2019
Today
5/31/2023
Next Earnings (Estimated)
7/20/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NURO
Employees
23
Year Founded
1996

Profitability

Net Income
$-4,420,000.00
Pretax Margin
-65.54%

Debt

Sales & Book Value

Annual Sales
$8.26 million
Book Value
$3.01 per share

Miscellaneous

Free Float
7,267,000
Market Cap
$8.19 million
Optionable
Not Optionable
Beta
2.29

Social Links


Key Executives

  • Shai N. Gozani
    Chairman, President & Chief Executive Officer
  • Thomas T. HigginsThomas T. Higgins
    Chief Financial Officer, Treasurer & Senior VP
  • Xuan Kong
    Chief Data Scientist
  • Brandi Damkier
    Vice President-Clinical Partnerships













NURO Stock - Frequently Asked Questions

How have NURO shares performed in 2023?

NeuroMetrix's stock was trading at $1.49 at the beginning of 2023. Since then, NURO shares have decreased by 29.9% and is now trading at $1.0450.
View the best growth stocks for 2023 here
.

Are investors shorting NeuroMetrix?

NeuroMetrix saw a decrease in short interest in May. As of May 15th, there was short interest totaling 2,700 shares, a decrease of 87.4% from the April 30th total of 21,500 shares. Based on an average daily trading volume, of 28,100 shares, the short-interest ratio is presently 0.1 days.
View NeuroMetrix's Short Interest
.

When is NeuroMetrix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 20th 2023.
View our NURO earnings forecast
.

How were NeuroMetrix's earnings last quarter?

NeuroMetrix, Inc. (NASDAQ:NURO) posted its quarterly earnings data on Thursday, October, 17th. The medical device company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01. The medical device company earned $2.09 million during the quarter, compared to analyst estimates of $3.94 million. NeuroMetrix had a negative net margin of 65.54% and a negative trailing twelve-month return on equity of 22.18%.

When did NeuroMetrix's stock split?

NeuroMetrix shares reverse split on the morning of Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 11th 2017. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What is Shai N. Gozani's approval rating as NeuroMetrix's CEO?

10 employees have rated NeuroMetrix Chief Executive Officer Shai N. Gozani on Glassdoor.com. Shai N. Gozani has an approval rating of 57% among the company's employees. This puts Shai N. Gozani in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeuroMetrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroMetrix investors own include Merit Medical Systems (MMSI), Palatin Technologies (PTN), Citigroup (C), Salesforce (CRM), Nokia Oyj (NOK), Ampio Pharmaceuticals (AMPE), ReWalk Robotics (RWLK), Aurora Cannabis (ACB), Advanced Micro Devices (AMD) and Vaxart (VXRT).

What is NeuroMetrix's stock symbol?

NeuroMetrix trades on the NASDAQ under the ticker symbol "NURO."

How do I buy shares of NeuroMetrix?

Shares of NURO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeuroMetrix's stock price today?

One share of NURO stock can currently be purchased for approximately $1.05.

How much money does NeuroMetrix make?

NeuroMetrix (NASDAQ:NURO) has a market capitalization of $8.19 million and generates $8.26 million in revenue each year. The medical device company earns $-4,420,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.

How can I contact NeuroMetrix?

NeuroMetrix's mailing address is 4B GILL STREET WOBURN, MASSACHUSETTS MA, 01801. The official website for the company is www.neurometrix.com. The medical device company can be reached via phone at (781) 890-9989, via email at neurometrix.ir@neurometrix.com, or via fax at 302-636-5454.

This page (NASDAQ:NURO) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -